Skip to Content

Quinapril Hydrochloride


Class: Angiotensin-Converting Enzyme Inhibitors
VA Class: CV800
Chemical Name: [3S-[2[R*(R)],3R*]]-2-[2-[[1-Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2 ,3,4-tetrahydro-3-isoquinolinecarboxylic acid monohydrochloride
Molecular Formula: C25H30N2O5•HCl
CAS Number: 82586-55-8
Brands: Accupril, Accuretic


  • May cause fetal and neonatal morbidity and mortality if used during pregnancy.1 47 65 66 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • If pregnancy is detected, discontinue quinapril as soon as possible.1 47 66


Nonsulfhydryl ACE inhibitor.1 2 3 47

Uses for Quinapril Hydrochloride


Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 2 4 28 47 500

ACE inhibitors are recommended as one of several preferred agents for the initial management of hypertension; other options include angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics.501 502 503 504 While there may be individual differences with respect to specific outcomes, these antihypertensive drug classes all produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.500 501 502 504 Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).500 501 502 503 504 515

ACE inhibitors may be preferred in hypertensive patients with heart failure, ischemic heart disease, diabetes mellitus, chronic kidney disease, or cerebrovascular disease or post-MI.500 501 502 504 520 523 524 525 526 527 534 535 536 543

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to ACE inhibitors.24 28 63 64 500 501 504 However, diminished response to an ACE inhibitor is largely eliminated when administered concomitantly with a calcium-channel blocker or thiazide diuretic.24 26 27 28 47 500 504

The optimum BP threshold for initiating antihypertensive drug therapy is controversial.501 504 505 506 507 508 515 523 530 Further study needed to determine optimum BP thresholds/goals; individualize treatment decisions.501 503 507 515 526 530

JNC 7 recommends initiation of drug therapy in all patients with uncomplicated hypertension and BP ≥140/90 mm Hg;500 JNC 8 panel recommends SBP threshold of 150 mm Hg for patients ≥60 years of age.501 Although many experts agree that SBP goal of <150 mm Hg may be appropriate for patients ≥80 years of age,502 504 505 530 application of this goal to those ≥60 years of age is controversial, especially for those at higher cardiovascular risk.501 502 505 506 508 511 515

In the past, initial antihypertensive drug therapy was recommended for patients with diabetes mellitus or chronic kidney disease who had BP ≥130/80 mm Hg;500 503 current hypertension management guidelines generally recommend a BP threshold of 140/90 mm Hg for these individuals (same as for the general population of patients without these conditions), although a goal of <130/80 mm Hg may still be considered.501 502 503 504 520 530 535 536 541

Heart Failure

Management of symptomatic heart failure, usually in conjunction with cardiac glycosides, diuretics, and β-adrenergic blocking agents.1 2 12 18 38

Diabetic Nephropathy

A recommended agent in the management of patients with diabetes mellitus and persistent albuminuria who have modestly elevated (30–300 mg/24 hours) or higher (>300 mg/24 hours) levels of urinary albumin excretion; slows rate of progression of renal disease in such patients.57 58 59 60 61 520 535 536

Quinapril Hydrochloride Dosage and Administration


BP Monitoring and Treatment Goals

  • Carefully monitor BP during initial titration or subsequent upward adjustment in dosage.500 501

  • When available, use evidence-based dosing information (i.e., dosages shown in randomized controlled trials to reduce complications of hypertension) to determine target dosages; target dosages usually can be achieved within 2–4 weeks but may take up to several months.501

  • If adequate BP response not achieved with a single antihypertensive agent, add a second drug with demonstrated benefit; if goal BP still not achieved with optimal dosages of 2 antihypertensive agents, add a third drug.501 May maximize dosage of the first drug before adding a second drug, or add a second drug before maximizing dosage of the initial drug.501

  • Consider initiating antihypertensive therapy with a combination of drugs if patient's BP exceeds goal BP by >20/10 mm Hg.500 501 503 504

  • Goal is to achieve and maintain optimal control of BP; individualize specific target BP based on consideration of multiple factors, including patient age and comorbidities, and currently available evidence from clinical studies.500 501 (See Hypertension under Uses.)


Oral Administration

Administer orally once or twice daily.1 47

Manufacturer makes no specific recommendation regarding administration of quinapril with meals;1 47 administer quinapril/hydrochlorothiazide fixed combinations without regard to meals.47 (See Food under Pharmacokinetics.)


Available as quinapril hydrochloride; dosage expressed in terms of quinapril.1 47

May minimize risk of hypotension in patients currently receiving diuretic therapy by discontinuing the diuretic, reducing diuretic dosage, or cautiously increasing salt intake prior to initiating quinapril; if diuretic therapy cannot be discontinued, initiate quinapril at a reduced dosage.600 (See Hypotension under Cautions and see the individual dosage sections in Dosage and Administration.)

Pediatric Patients


Some experts recommend an initial dosage of 5–10 mg once daily.62 Increase dosage as necessary to a maximum dosage of 80 mg once daily.62


Quinapril Therapy

Initially, 10 or 20 mg once daily in patients not receiving a diuretic.2 3 28 600 Adjust dosage at ≥2-week intervals to achieve BP control.1

In patients currently receiving diuretic therapy, discontinue diuretic, if possible, 2–3 days before initiating quinapril.600 May resume diuretic therapy if BP not controlled adequately with quinapril alone.600 If diuretic cannot be discontinued, initiate quinapril at a dose of 5 mg under close medical supervision for several hours until BP has stabilized.600

Usual maintenance dosage: 20–80 mg daily, given in 1 dose or 2 divided doses.28 600

If effectiveness diminishes toward end of dosing interval in patients treated once daily, consider increasing dosage or administering drug in 2 divided doses.1 28

If intolerable adverse effects occur, consider dosage reduction; if adverse effects worsen or fail to resolve, may need to discontinue and switch to another antihypertensive drug class.501

Quinapril/Hydrochlorothiazide Fixed-combination Therapy

Manufacturer states fixed-combination preparation should not be used for initial antihypertensive therapy.47

If BP is not adequately controlled by monotherapy with quinapril or hydrochlorothiazide, can switch to the fixed-combination preparation containing quinapril 10 mg and hydrochlorothiazide 12.5 mg or, alternatively, quinapril 20 mg and hydrochlorothiazide 12.5 mg.47 Adjust dosage of either or both drugs according to patient’s response.47

If BP is controlled by monotherapy with hydrochlorothiazide 25 mg daily but potassium loss is problematic, can switch to fixed-combination preparation containing quinapril 10 mg and hydrochlorothiazide 12.5 mg or, alternatively, quinapril 20 mg and hydrochlorothiazide 12.5 mg.47

If BP is controlled with quinapril 20 mg and hydrochlorothiazide 25 mg (administered separately) and if no clinically important electrolyte disturbance is observed, can switch to the fixed-combination preparation containing these corresponding doses for convenience.47

Heart Failure

Initially, 5 mg twice daily.1 Monitor closely for ≥2 hours until BP has stabilized.1 To minimize risk of hypotension, reduce diuretic dosage, if possible.1

Adjust dosage at weekly intervals to reach usual dosage.1

Usual dosage: 20–40 mg daily, given in 2 equally divided doses.1

Prescribing Limits

Pediatric Patients


Maximum 80 mg daily.62

Special Populations

Renal Impairment


Initially, 10 mg once daily in adults with Clcr >60 mL/minute; 5 mg once daily in those with Clcr 30–60 mL/minute; or 2.5 mg once daily in those with Clcr 10–30 mL/minute.1 Titrate at 2-week intervals until BP is controlled.1 (See Renal Impairment under Cautions.)

Quinapril/hydrochlorothiazide fixed combinations are not recommended in patients with severe renal impairment (Clcr ≤30 mL/minute or Scr >3 mg/dL).47

Heart Failure

Initially (first day), 5 mg in patients with moderate renal impairment (Clcr >30 mL/minute) or 2.5 mg in patients with severe renal impairment (Clcr 10–30 mL/minute) under close medical supervision.1 If well tolerated, administer as twice-daily regimen on subsequent days.1 Titrate at weekly intervals based on clinical and hemodynamic response.1

Geriatric Patients


Initially, 10 mg once daily as monotherapy.1 Adjust dosage at ≥2-week intervals to achieve BP control.1

Cautions for Quinapril Hydrochloride


  • Known hypersensitivity (e.g., history of angioedema) to quinapril or another ACE inhibitor.1 47



Hepatic Effects

Clinical syndrome that usually is manifested initially by cholestatic jaundice and may progress to fulminant hepatic necrosis (occasionally fatal) reported rarely with ACE inhibitors.1 47

If jaundice or marked elevation of liver enzymes occurs, discontinue drug and monitor patient.1 47


Possible symptomatic hypotension.1 47 Risk of marked hypotension, sometimes associated with oliguria and/or progressive azotemia and, rarely, acute renal failure and/or death, in patients with heart failure, hyponatremia, or severe volume and/or salt depletion; patients undergoing dialysis; and those receiving diuretic therapy with high doses, recent increase in dosage, or recent intensive diuresis.600 Potential for MI or stroke in patients with ischemic cardiovascular or cerebrovascular disease.1 47

Hypotension may occur in patients undergoing surgery or during anesthesia with agents that produce hypotension; recommended treatment is fluid volume expansion.1 47

To minimize potential for hypotension, consider recent antihypertensive therapy, extent of BP elevation, sodium intake, fluid status, and other clinical conditions.1 47 May minimize potential for hypotension in patients at risk of excessive hypotension by withholding diuretic therapy (except in patients with heart failure), reducing diuretic dosage, and/or cautiously increasing sodium intake (except in patients with heart failure) prior to initiation of quinapril.1 47 600 (See Dosage under Dosage and Administration.)

In patients at risk of excessive hypotension, initiate therapy under close medical supervision; monitor closely for first 2 weeks following initiation of quinapril or any increase in quinapril or diuretic dosage.1 47

If excessive hypotension occurs, immediately place patient in supine position and, if necessary, administer IV infusion of 0.9% sodium chloride solution.1 47 Quinapril therapy usually can be continued following restoration of volume and BP.1 47 If symptomatic hypotension develops, dosage reduction or discontinuance of quinapril or diuretic may be necessary.1 47

Hematologic Effects

Neutropenia and agranulocytosis reported with captopril; risk appears to depend principally on presence of renal impairment and/or presence of collagen vascular disease.1 47 Data insufficient to rule out similar incidence of agranulocytosis with quinapril.1 47

Consider monitoring leukocytes in patients with collagen vascular disease and/or renal disease.1 47

Fetal/Neonatal Morbidity and Mortality

Possible fetal and neonatal morbidity and mortality when used during pregnancy.1 47 65 66 (See Boxed Warning.) Such potential risks occur throughout pregnancy, especially during the second and third trimesters.66

Also may increase the risk of major congenital malformations when administered during the first trimester of pregnancy.65 66

Discontinue as soon as possible when pregnancy is detected, unless continued use is considered lifesaving.66 Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy.1 47

Sensitivity Reactions

Anaphylactoid reactions and/or head and neck angioedema possible; if associated with laryngeal edema, may be fatal.1 47 b Immediate medical intervention (e.g., epinephrine) for involvement of tongue, glottis, or larynx.1 47

Intestinal angioedema reported; sometimes occurs in patients with no prior history of facial angioedema.1 b Manifestations include abdominal pain (with or without nausea or vomiting).1 b Consider intestinal angioedema in the differential diagnosis of patients receiving ACE inhibitors presenting with abdominal pain.1 b

Anaphylactoid reactions reported in patients receiving ACE inhibitors while undergoing LDL apheresis with dextran sulfate absorption or following initiation of hemodialysis that utilized high-flux membrane.1 47

Life-threatening anaphylactoid reactions reported in at least 2 patients receiving ACE inhibitors while undergoing desensitization treatment with hymenoptera venom.1 47

Contraindicated in patients with a history of angioedema associated with ACE inhibitors.1 47

General Precautions

Renal Effects

Transient increases in BUN and Scr possible, especially in patients with preexisting renal impairment or those receiving concomitant diuretic therapy.1 47 Possible increases in BUN and Scr in patients with unilateral or bilateral renal artery stenosis; generally reversible following discontinuance of ACE inhibitor and/or diuretic.1 47

Possible oliguria, progressive azotemia, and, rarely, acute renal failure and/or death in patients with severe heart failure.1 47

Closely monitor renal function for the first few weeks of therapy in hypertensive patients with unilateral or bilateral renal-artery stenosis.1 47 Some patients may require dosage reduction or discontinuance of ACE inhibitor or diuretic.1 47


Possible hyperkalemia, especially in patients with renal impairment or diabetes mellitus and those receiving drugs that can increase serum potassium concentration (e.g., potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes).1 47 (See Specific Drugs under Interactions.)

Monitor serum potassium concentration carefully in these patients.1 47


Persistent and nonproductive cough; resolves after drug discontinuance.1 47

Use of Fixed Combinations

When used in fixed combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with hydrochlorothiazide.47

Specific Populations


Category C (1st trimester); Category D (2nd and 3rd trimesters).1 47 (See Fetal/Neonatal Morbidity and Mortality under Cautions and see Boxed Warning.)


Distributed into milk.1 47 Caution if used in nursing women.47 3 4

Pediatric Use

Safety and efficacy remain to be fully established in children;1 47 however, some experts have recommended dosages for hypertension based on current limited clinical experience.62

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1 47 However, cautious dosing recommended due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly.1 47

Renal Impairment

Deterioration of renal function may occur. (See Renal Effects under Cautions.)1 47

Initial dosage adjustment recommended in patients with renal impairment.1 (See Renal Impairment under Dosage and Administration.) Safety and efficacy not established in patients with Clcr <10 mL/minute.1 47

Quinapril/hydrochlorothiazide fixed combinations are not recommended in patients with severe renal impairment (Clcr ≤30 mL/minute or Scr >3 mg/dL).47

Hepatic Impairment

Use with caution in patients with hepatic impairment or progressive liver disease.47

Black Patients

BP reduction may be smaller in black patients compared with nonblack patients.1 24 25 47 48 49 (See Hypertension under Uses.)

Higher incidence of angioedema reported with ACE inhibitors in black patients compared with other races.1 47 49 500

Common Adverse Effects

Patients with hypertension: Headache, dizziness, fatigue, cough, nausea, vomiting, abdominal pain.1 47 With fixed combination preparation, myalgia, virus infection, rhinitis, back pain, diarrhea, upper respiratory tract infection, insomnia, somnolence, bronchitis, dyspepsia, asthenia, pharyngitis, vasodilation, vertigo, chest pain.47

Patients with heart failure: Dizziness, cough, fatigue, nausea, vomiting, chest pain, hypotension, dyspnea, diarrhea, headache, myalgia, rash, back pain, increased serum creatinine concentration, increased BUN.1

Interactions for Quinapril Hydrochloride

Drugs That Interact with Magnesium

Possible decreased absorption of drugs that interact with magnesium, possibly due to high magnesium content in quinapril-containing preparations.1 47

Specific Drugs





Pharmacokinetic interaction unlikely1


Pharmacokinetic interaction unlikely1 47


Pharmacokinetic interaction unlikely1 47


Increased hypotensive effect1 47

If possible, discontinue diuretic before initiating quinapril1 47 (See Dosage under Dosage and Administration)

Diuretics, potassium-sparing (amiloride, spironolactone, triamterene)

Enhanced hyperkalemic effect1 47

Use with caution; monitor serum potassium concentrations frequently1 47


Increased serum lithium concentrations; possible toxicity1 47

Monitor serum lithium concentrations frequently1 47

Potassium supplements or potassium-containing salt substitutes

Enhanced hyperkalemic effect1 47

Use with caution; monitor serum potassium concentrations frequently1 47


Pharmacokinetic interaction unlikely1 47


Decreased tetracycline absorption1 47


Pharmacologic interaction unlikely1 47

Quinapril Hydrochloride Pharmacokinetics



About 60% of oral dose is absorbed.1 47

Peak plasma concentrations of quinapril and quinaprilat are achieved within 1 and 2 hours, respectively.1 47


Following a single oral dose, antihypertensive effects are observed within 1 hour, with peak BP reduction at 2–4 hours.1 47

During chronic therapy, maximum antihypertensive effect is achieved after 1–2 weeks.1 47


Inhibition of >80% of ACE activity persists for about 24 hours.1 47 Inhibition of 75% of the pressor response to angiotensin I persists for about 4 hours.1 47


High-fat meals result in moderate (25–30%) reductions in rate and extent of absorption of quinapril.1 47 When quinapril/hydrochlorothiazide combination is administered with high-fat meals, rate of quinapril absorption is reduced by 14%, but extent of absorption is unaffected.47

Special Populations

Decreased quinaprilat concentrations in patients with alcoholic cirrhosis.1 47



Quinapril and quinaprilat do not cross the blood-brain barrier.1 47

Crosses the placenta in rats.1 47 Distributed into human milk.1 47

Plasma Protein Binding

97% for both quinapril and quinaprilat.1 47



Metabolized principally to an active metabolite, quinaprilat (approximately 38% of oral dose).1 47

Elimination Route

Eliminated principally in urine (as metabolites).1 47

Not removed by hemodialysis or peritoneal dialysis.1 47


Quinaprilat: Elimination: 2 hours; prolonged terminal phase of 25 hours.1 47

Special Populations

In patients with renal impairment, elimination half-life increases with decreasing Clcr.1 47

Decreased elimination of quinaprilat in patients ≥65 years of age.1 47





Conventional tablets: 15–30°C.1 Protect from light.1

Fixed combination tablets: 20–25°C.47


  • Prodrug; not pharmacologically active until hydrolyzed in the liver to quinaprilat.1 2 3 47

  • Suppresses the renin-angiotensin-aldosterone system.1 47

Advice to Patients

  • Risk of angioedema, anaphylactoid reactions, or other sensitivity reactions.1 47 Importance of reporting sensitivity reactions (e.g., edema of face, eyes, lips, tongue, or extremities; hoarseness; swallowing or breathing with difficulty) immediately to clinician and of discontinuing the drug.1 47

  • Importance of reporting signs of infection (e.g., sore throat, fever).1 47

  • Risk of hypotension.1 47 Importance of informing clinicians promptly if lightheadedness or fainting occurs.1 47

  • Importance of adequate fluid intake; risk of volume depletion with excessive perspiration, dehydration, vomiting, or diarrhea.1 47

  • Risks of use during pregnancy.1 47 65 66 (See Boxed Warning.)

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs (including salt substitutes containing potassium).1 47

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 47

  • Importance of advising patients of other important precautionary information.1 47 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Quinapril Hydrochloride


Dosage Forms


Brand Names



Tablets, film-coated

5 mg (of quinapril)*

Accupril (scored)


Quinapril Hydrochloride Tablets

10 mg (of quinapril)*



Quinapril Hydrochloride Tablets

20 mg (of quinapril)*



Quinapril Hydrochloride Tablets

40 mg (of quinapril)*



Quinapril Hydrochloride Tablets

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Quinapril Hydrochloride Combinations


Dosage Forms


Brand Names



Tablets, film-coated

10 mg (of quinapril) with Hydrochlorothiazide 12.5 mg*

Accuretic (scored)


Quinapril Hydrochloride and Hydrochlorothiazide Tablets



20 mg (of quinapril) with Hydrochlorothiazide 12.5 mg*



Quinapril Hydrochloride and Hydrochlorothiazide Tablets



20 mg (of quinapril) with Hydrochlorithiazide 25 mg*



Quinapril Hydrochloride and Hydrochlorothiazide Tablets



AHFS DI Essentials. © Copyright, 2016, American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

Date published: May 01, 2004
Last reviewed: February 12, 2015
Date modified: February 08, 2016


1. Parke Davis. Accupril (quinapril hydrochloride) tablets prescribing information. New York, NY; 2003 Feb.

2. Wadworth AN, Brogden RN. Quinapril: a review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders. Drugs. 1991; 41:378-99. [PubMed 1711445]

3. Anon. Quinapril for hypertension. Med Lett Drugs Ther. 1992; 34:27-8. [PubMed 1542279]

4. McAreavey D, Robertson JI. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs. 1990; 40:326-45. [PubMed 2226219]

5. Squibb. Capoten (captopril) tablets prescribing information. In: Physician’s desk reference. 47th ed. Montvale, NJ: Medical Economics Company Inc; 1993:2356-62.

6. Reviewers’ comments in Enalaprilat/Enalapril 24:32.04 (personal observations).

8. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. [PubMed 6150424]

10. US Food and Drug Administration. Dangers of ACE inhibitors during second and third trimesters of pregnancy. FDA Med Bull. 1992; 22:2.

12. Cetnarowski-Cropp AB. Quinapril: a new second-generation ACE inhibitor. DICP. 1991; 25:499-504. [IDIS 280753] [PubMed 2068835]

13. Packer M, Lee WH, Medina N. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987; 106:346-54. [IDIS 226752] [PubMed 3028221]

14. Packer M, Lee WH, Yushak M. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986; 315:847-53. IDIS 221364.

15. Oster JR, Materson BL. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensive-converting enzyme inhibitors. Arch Intern Med. 1992; 152:704-10. [IDIS 295733] [PubMed 1558426]

16. Mason N. Angiotensin-converting enzyme inhibitors and renal function. DICP. 1990; 24:496-505. [IDIS 266588] [PubMed 2188438]

17. Gottlieb SS, Robinson S, Weir MR et al. Determinant of the renal response to ACE inhibition in patients with congestive heart failure. Am Heart J. 1992; 124:131-6. [IDIS 298621] [PubMed 1615796]

18. Riegger GA. The effects of ACE inhibitors on exercise capacity in the treatment of congestive heart failure. J Cardiovasc Pharmacol. 1990; 15(Suppl 2):S41-6.

19. Frank GJ. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects? J Hypertension. 1989; 7(Suppl 5):S17-22.

20. Baker DW, Konstam MA, Bottorff M. Management of heart failure JAMA. 1994; 272:1361-6.

21. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol. 1994; 43:151-63. [PubMed 8181869]

22. Sharpe N. ACE inhibitors versus diuretics: when to choose which drug: Cardiovasc Drugs Ther. 1993; 7:877-9. Abstract.

23. Magestro P (Parke-Davis, Morris Plains, NJ); personal communication.

24. Saundes E. Tailoring treatment to minority patients. Am J. 1990; 88(Suppl 3B):21-3S.

25. Chrysant SG, Danise K, Kern DC et al. Racial differences in pressure, volume and renin interrelationships in essential hypertension, Hypertension. 1979; 1:136-41.

26. Holland OB, Kuhnert L, Campbell WB et al. Synergistic effect of captopril with hydrochlorothiazide for the treatment of low-renin hypertensive black patients. Hypertension. 1983; 5:235-9. [PubMed 6337951]

27. Ferguson RK, Vlasses PH, Rotmesch HH. Clinical applications of angiotensin-enzyme inhibitors. Am J Med. 1984; 77:690-8.

28. Parke-Davis. Accupril (quinapril hydrochloride) tablets prescribing information. In: Physicians’ desk reference. 51st ed. Montvale, NJ: Medical Economics Company Inc; 1997(Suppl A):A241.

29. Rey E, LeLorier J, Burgess E et al. Report of the Canadian Hypertension Society consensus conference: 3. pharmacologic treatment of hypertensive disorders in pregnancy. CMAJ. 1997; 157:1245-54. [IDIS 396283] [PubMed 9361646]

30. American College of Obstetricians and Gynecologists. ACOG technical bulletin No. 219: hypertension in pregnancy. 1996 Jan.

31. Hanssens M, Keirse MJ, Van Assche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991; 78:128-35. [IDIS 284531] [PubMed 2047053]

32. Brent Rl, Beckman D. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology counselors. Teratology. 1991; 43:543-6. [PubMed 1882342]

33. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992; 80:429-32. [IDIS 300973] [PubMed 1495700]

34. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med. 1996; 335:257-65. [IDIS 369138] [PubMed 8657243]

35. Barr M, Cohen MM. ACE inhibitor fetopathy and hypocalvaria: the kidney-skull connection. Teratology. 1991; 44:485-95. [PubMed 1771591]

36. US Food and Drug Administration. Dangers of ACE inhibitors during pregnancy. FDA Med Bull. 1992; 22:2.

37. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341:709-17. [IDIS 431313] [PubMed 10471456]

38. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9A-38A.

39. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med. 1999; 341:753-4. [IDIS 431314] [PubMed 10471464]

40. Anon. Spironolactone for heart failure. Med Lett Drugs Ther. 1999; 41:81-2. [PubMed 10505071]

41. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999; 100:2312-8. [IDIS 440440] [PubMed 10587334]

43. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. [PubMed 10818056]

44. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. [PubMed 10818055]

45. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. [IDIS 452007] [PubMed 10977801]

46. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site.

47. Parke Davis. Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets prescribing information. New York, NY; 2001 Sep.

48. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60. [IDIS 490723] [PubMed 12479770]

49. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. [IDIS 490721] [PubMed 12479763]

53. Novartis. Diovan (valsartan) tablets prescribing information. East Hanover, NJ; 2002 Aug.

57. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329:1456-62. [IDIS 321612] [PubMed 8413456]

58. Remuzzi G. Slowing the progression of diabetic nephropathy. N Engl J Med. 1993; 329:1496-7. [PubMed 8413463]

59. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. [IDIS 365188] [PubMed 8622249]

60. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994; 271:275-9. [IDIS 324307] [PubMed 8295285]

61. Fournier A. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1994; 330:937. [PubMed 8114873]

62. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(Suppl 2):555-76.

63. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. [IDIS 531054] [PubMed 15811979]

64. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. Editorial. [IDIS 531056] [PubMed 15811986]

65. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354:2443-51. [PubMed 16760444]

66. Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. From FDA website.

67. Schwarz Pharma. Univasc™ (moexipril hydrochloride) tablets product monograph. Milwaukee, WI; 1995 July.

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. [PubMed 24352797]

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. [PubMed 23817082]

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. [PubMed 24243703]

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. [PubMed 24341872]

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. [PubMed 24424788]

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. [PubMed 24549531]

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. [PubMed 24352710]

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. [PubMed 24352759]

511. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31:2115-27. [PubMed 19139601]

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. [PubMed 24591473]

520. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014; 37 Suppl 1:S14-80. [PubMed 24357209]

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471. [PubMed 23166211]

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327. [PubMed 23741058]

525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458-73. [PubMed 22052934]

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. [PubMed 24788967]

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. [PubMed 23247304]

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. [PubMed 24641124]

534. Qaseem A, Hopkins RH, Sweet DE et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159:835-47. [PubMed 24145991]

535. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62:201-13. [PubMed 23684145]

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

541. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33:1635-701. [PubMed 22555213]

543. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease (2002). From National Kidney Foundation website.

600. Parke Davis. Accupril (quinapril hydrochloride) tablets prescribing information. New York, NY; 2014 May.

b. Parke Davis. Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets prescribing information. New York, NY; 2003 Aug.